The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target.

Epidemiology Genetics Lipoprotein(a) Measurement Oxidized phospholipids Pathophysiology mRNA targeting therapy

Journal

Atherosclerosis
ISSN: 1879-1484
Titre abrégé: Atherosclerosis
Pays: Ireland
ID NLM: 0242543

Informations de publication

Date de publication:
05 2022
Historique:
received: 13 04 2022
accepted: 14 04 2022
entrez: 23 5 2022
pubmed: 24 5 2022
medline: 26 5 2022
Statut: ppublish

Résumé

Atherosclerosis, as the official journal of the European Atherosclerosis Society (EAS), decided that it would be timely to publish a comprehensive collection of review articles on lipoprotein(a). Spanning the last decade or two, this lipoprotein has become a further target in the fight against atherosclerotic cardiovascular disease. In that time, detailed knowledge about lipoprotein(a) has grown tremendously. Therefore, we decided not to have just one review article covering all aspects of lipoprotein(a), but rather to invite established experts in the field to write in-depth review articles on various aspects of lipoprotein(a). Collectively, these articles cover epidemiology, genetics, non-genetic influences, the influence of ethnicity, basic scientific investigations on the pathogenicity of lipoprotein(a), therapeutic developments to lower lipoprotein(a), and the challenging related to measurement of lipoprotein(a). The end result is a collection of 13 articles, which should be considered as the most comprehensive overview on the lipoprotein(a) field currently available. At the same time, the EAS invited the scientific community to submit original research papers in various areas of lipoprotein(a) research. This has resulted in an additional 15 articles that are part of an extended Atherosclerosis Special Issue along with the invited review articles.

Identifiants

pubmed: 35606069
pii: S0021-9150(22)00196-4
doi: 10.1016/j.atherosclerosis.2022.04.017
pii:
doi:

Substances chimiques

Lipoprotein(a) 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-6

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Marlys L Koschinsky (ML)

Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada; Department of Physiology & Pharmacology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada. Electronic address: mlk@robarts.ca.

Florian Kronenberg (F)

Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: Florian.Kronenberg@i-med.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH